ClinicalTrials.gg
CompletedNCT01828398Updated Jan 16, 2014

tDCS and Robotic Therapy in Stroke

A Phase 2 interventional study of real-tDCS + UE robot-assisted therapy and sham-tDCS + UE robot-assisted therapy in Stroke and Upper Extremity Impairments, sponsored by University Hospital of Ferrara. Completed at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-01-16.

Sponsored by University Hospital of Ferrara · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

After stroke a limited motor recovery in the paretic upper limb accounts for a large proportion of the disabling sequelae. Only about 15% of those with initial complete upper limb paralysis after stroke recover functional use of their impaired arm in daily life.

The aim of this study is to test the effects of tDCS combined with upper extremity robot-assisted therapy on stroke survivors.

02

Conditions studied

  • Stroke
  • Upper Extremity Impairments

Browse trials for

03

In context

Stroke

7,441 studies on the registry are indexed under Stroke; 2,012 are open to participants now.

This study's enrollment of 40 is below the median of 50 across 5,482 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

University Hospital of Ferrara is the lead sponsor of 113 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females subjects. Age > 18 years.
  • Diagnosis of first ischemic stroke
  • Impairment of the upper limb
  • Trunk control defined in the Trunk-Control Test (TCT), with a score > 50.

Exclusion criteria

Exclusion Criteria:

  • anyone who does not have adequate understanding of verbal or written information in Italian sufficient to complete any test
  • Impaired cognitive functioning: score less than 24 on the Mini Mental Status Examination (MMSE)
  • contraindications to single-pulse transcranial magnetic stimulation (TMS)(TMS will be used to measure cortical excitability): presence of a history of epilepsy, frequent headaches or neck pain, implantable devices (ventriculoperitoneal shunts, pacemakers, intrathecal pumps, intracranial metal implants)
  • Contraindications to tDCS: intracranial metal implants that can be stimulated, incorrectly positioned or over-heated by the electric current
  • Neurological or psychiatric pathology
  • severe cardio-pulmonary, renal, hepatic diseases
  • Pregnancy
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Sham comparator
    sham-tDCS + UE robot-assisted therapy

    This group will receive the same robot-assisted therapy of the intervention group, in association of sham-tDCS. This consists in a 30 seconds stimulation, with the same instrumentation and electrodes placement. This method of sham stimulation was previously validated.

    Device: sham-tDCS + UE robot-assisted therapy

  • Experimental
    real-tDCS + UE robot-assisted therapy

    This group will receive continuous stimulation lasting 30 minutes during the session of robot-assisted therapy. The training session, which includes multiplanar, repetitive and target reaching movements, will be given 5 times a week for 2 weeks(REO Therapy System; Motorika, Medical LTD, Israel). Each session will last about 30 minutes. Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the affected hemisphere and the cathode on the contralateral M1 area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries (Brainstim, EMS, Italy). This continuous stimulation lasted 30 minutes, with an intensity of 1mA.

    Device: real-tDCS + UE robot-assisted therapy

Interventions

  • Devicereal-tDCS + UE robot-assisted therapy
  • Devicesham-tDCS + UE robot-assisted therapy
06

What researchers measure

Primary outcomes

  1. Fugl-Meyer Upper Extremity

    Measure of upper extremity motor impairment. The upper extremity score ranges from 0-66.

    Time frame: A week prior to treatment beginning

Secondary outcomes

  1. Box and Block Test

    Test for gross motor function. It counts the number of blocks that can be transported from one compartment of a box to another compartment within 1 minute.

    Time frame: A week prior to treatment beginning

  2. Ashworth Modified Scale

    a 6 point measure of spasticity. We will assess the spasticity at the shoulder, elbow and, wrist

    Time frame: A week prior to treatment beginning

  3. Motor Activity Log (MAL)

    Assessment of the change in real-world arm use in activities of daily living. Subjects are asked to score the quality of movement as well as amount of use of the affected arm in a number of common daily activities.

    Time frame: A week prior to treatment beginning

  4. Assessment of cortical excitability (TMS)

    MEP of upper limb muscles (first dorsal interosseous) will be recorded with surface EMG electrodes. neurophysiological parameters analyzed: * motor threshold at rest * MEP recruitment curve at rest * MEP amplitude

    Time frame: A week prior to treatment beginning

07

Study locations

1 site
  • Ferrara University Hospital
    Ferrara, Italy
08

References and documents

Publications

  • Elsner B, Kugler J, Pohl M, Mehrholz J. Transcranial direct current stimulation (tDCS) for improving activities of daily living, and physical and cognitive functioning, in people after stroke. Cochrane Database Syst Rev. 2020 Nov 11;11(11):CD009645. doi: 10.1002/14651858.CD009645.pub4. PubMed 33175411 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01828398
Responsible party
Sofia Straudi, MD (MD, University Hospital of Ferrara) — Principal investigator
First posted
Apr 10, 2013
Start date
Nov 2011
Primary completion
Sep 2013
Completion
Nov 2013
Last update
Jan 16, 2014

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion